Stock Code: 300683
Stock Abbreviation: Hite Bio-pharmaceutical
Announcement No.: 2026-033
Wuhan Hite Bio-pharmaceutical Co., Ltd.
Announcement on the Acceptance of the Clinical Trial Application for Recombinant Human Tumor Necrosis Factor Receptor Superfamily Member 10a Fusion Protein for Injection
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and there are no false records, misleading statements, or major omissions.
Wuhan Hite Bio-pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") recently received the "Acceptance Notice" issued by the National Medical Products Administration (hereinafter referred to as the "NMPA"). The Company's application for a clinical trial of recombinant human tumor necrosis factor receptor superfamily member 10a fusion protein for injection (Product Name: Shaait) for the indication of unresectable or metastatic classic chondrosarcoma has been accepted. The relevant information is hereby announced as follows:
I. Basic Information of the Clinical Trial Application
Product Name: Recombinant Human Tumor Necrosis Factor Receptor Superfamily Member 10a Fusion Protein for Injection
Application Matter: Domestic Production Drug Registration Clinical Trial
Acceptance Number: CXSL2600766
Indication: Unresectable or metastatic classic chondrosarcoma
Applicant: Wuhan Hite Bio-pharmaceutical Co., Ltd.
Conclusion: In accordance with the provisions of Article 32 of the "Administrative Licensing L